Federal Law Empowers Pharmacists to Prescribe Buprenorphine as States Race to Implement Access

When Maryland legislators convened Tuesday morning to consider Senate Bill 562, the testimony from public health advocates carried an urgency shaped by contradictory realities: overdose deaths falling for the fourth consecutive year to a decade low, yet 1,315 residents still dying from drug poisoning in 2025 alone. The bill would allow Maryland pharmacists registered with the Drug Enforcement Administration to prescribe buprenorphine, the gold-standard medication for opioid use disorder, under collaborative agreements with physicians.

The timing reflects more than state initiative. Three months earlier, on December 1, 2025, President Trump signed the SUPPORT for Patients and Communities Reauthorization Act of 2025 into law, creating the first federal pathway for pharmacists to independently prescribe buprenorphine after completing eight hours of continuing education offered through the American Pharmacists Association and the Accreditation Council for Pharmacy Education. Maryland's SB 562 represents the legislative infrastructure states must now build to translate federal authorization into clinical reality.

"By expanding access and reducing barriers to evidence-based treatment for OUD through pharmacist prescribing of buprenorphine, SB 562 would prepare Maryland to continue its fight against the overdose crisis," Stacey McKenna, associate director of healthier communities at the R Street Institute, told the House Committee on Health during Tuesday's hearing. "It would save lives, improve people's health and well-being, increase community safety, and reduce costs to taxpayers."

The path to this moment stretched across decades of regulatory restriction. Before December 2022, federal law required prescribers to obtain a special "X-waiver" to prescribe buprenorphine, creating bureaucratic barriers that limited the medication's availability precisely when the opioid crisis demanded expansion. The Mainstreaming Addiction Treatment Act of 2022 eliminated the X-waiver requirement for physicians and nurse practitioners, but pharmacists remained constrained by patchwork state regulations that varied wildly in scope and stringency.

The SUPPORT Act changed the equation by establishing federal continuing education standards that supersede state-level variability. Pharmacists who complete the eight-hour training and register with the DEA can now prescribe buprenorphine regardless of whether their state legislature has explicitly authorized the practice. At least ten states already permit pharmacist prescribing under collaborative practice agreements; two states allow independent prescribing without physician oversight. The federal law doesn't mandate state participation, but it creates permission structure that makes restrictive state policies increasingly difficult to defend.

Medication That Keeps People Alive

Buprenorphine works by binding to opioid receptors in the brain differently than heroin or fentanyl, preventing withdrawal symptoms and reducing cravings without producing euphoria. The clinical evidence supporting its effectiveness has accumulated over two decades: patients taking buprenorphine are approximately 60 percent less likely to experience fatal overdose than those receiving non-medication treatment. A Veterans Affairs pharmacist-led prescribing program documented 86.9 percent treatment retention at 90 days, exceeding typical physician-directed outcomes.

The mechanism matters less than the outcome: people taking buprenorphine stay alive long enough to rebuild lives disrupted by addiction. They're less likely to use illicit drugs, less likely to engage in criminal activity, more likely to maintain employment and housing. Compared to behavioral therapy alone, medication-assisted treatment produces substantially higher rates of long-term recovery.

Yet access remains maddeningly insufficient. Maryland's 500-plus insured residents per 100,000 living with opioid use disorder face treatment landscapes where appointment wait times stretch weeks or months, where clinics require upfront payment, where rural counties offer no prescribers at all. Expanding Maryland's roughly 1,000 pharmacies into potential buprenorphine access points would fundamentally alter treatment geography.

"With roughly 1,000 pharmacies in the state of Maryland, expanding pharmacists' scope of practice to allow them to prescribe buprenorphine would dramatically increase the state's pool of potential buprenorphine prescribers," McKenna's testimony noted. Pharmacists already prescribe contraception, naloxone for overdose reversal, and pre-exposure prophylaxis for HIV prevention. Buprenorphine represents a logical extension of expertise they've demonstrated in managing chronic conditions requiring careful dosing and monitoring.

The economic logic compounds clinical benefits. Each opioid use disorder case costs Maryland $1.4 million annually in criminal justice expenses, healthcare utilization, lost productivity, and social services. Expanding buprenorphine access doesn't eliminate those costs entirely, but research consistently shows medication-assisted treatment reduces emergency department visits, decreases incarceration rates, and improves employment outcomes—all of which translate into measurable fiscal impact.

Diversion Concerns Meet Evidence

Resistance to pharmacist prescribing typically centers on diversion: the concern that increasing buprenorphine availability will flood streets with medication diverted from legitimate treatment channels. The empirical record complicates that narrative.

Buprenorphine diversion does occur, but studies examining why people use diverted medication reveal therapeutic rather than recreational intent. Most individuals using diverted buprenorphine report doing so to manage withdrawal symptoms, reduce their use of illicit opioids, or self-medicate when formal treatment remains inaccessible. In communities where treatment capacity falls short of need, buprenorphine diversion sometimes increases—but those increases correlate with reduced overdose mortality, suggesting diverted medication serves as stopgap harm reduction when systems fail.

A 2023 harm reduction modeling study published in Harm Reduction Journal found that expanding formal buprenorphine access actually reduces diversion by eliminating the scarcity that drives informal markets. When people can access medication through legitimate channels without bureaucratic obstacles, the incentive to seek diverted supplies diminishes.

Maryland's overdose trajectory supports the harm reduction argument. Deaths fell for four consecutive years even as the state expanded medication access through jail-based treatment programs, rapid access prescribing initiatives, and point-of-service drug checking. The pattern suggests that meeting people where they are with evidence-based interventions produces better outcomes than restricting access based on theoretical diversion concerns disconnected from how people actually use substances.

Medical Community Support

The American Pharmacists Association's advocacy for the SUPPORT Act provision reflected years of groundwork demonstrating pharmacist competency in addiction medicine. Surveys of physicians and other prescribers show broad acceptance of pharmacist involvement in opioid use disorder treatment, particularly when collaborative practice agreements define roles and communication protocols clearly.

That professional consensus matters for implementation. Maryland's SB 562 requires pharmacists to operate under agreements with physicians, creating accountability structures that address legitimate concerns about patient safety while avoiding the regulatory restrictions that have historically limited buprenorphine availability. The collaborative model has worked in states like Idaho and New Mexico, where pharmacist prescribing increased treatment access without documented increases in adverse outcomes or diversion.

Critics note that eight hours of continuing education may not fully prepare pharmacists for the complexity of addiction medicine, particularly when treating patients with co-occurring mental health conditions or histories of polysubstance use. Fair concern, but the same critique applies to the minimal addiction training most physicians receive during medical school. Pharmacists enter continuing education with expertise in medication management, drug interactions, and chronic disease monitoring—precisely the skill set buprenorphine treatment demands once initial assessment establishes appropriateness.

The more substantive implementation question involves how collaborative agreements will function in practice. Will physicians embrace partnerships that expand treatment capacity, or will fear of liability create bottlenecks that undermine the legislation's intent? Will insurance companies reimburse pharmacist prescribing at rates that make the service financially viable? Will community health centers and safety-net providers integrate pharmacists into care teams, or will fragmented systems leave pharmacists operating in isolation without adequate support for complex cases?

What Maryland Decides

Maryland's consideration of SB 562 arrives amid national conversation about whether recent overdose declines represent durable progress or temporary reprieve. Provisional CDC data shows opioid deaths falling nearly 50 percent since the June 2023 peak, a decline researchers attribute partly to disrupted fentanyl supply chains and partly to expanded harm reduction and treatment access.

Maryland contributed to that progress through policy choices that prioritized health responses over punitive approaches. Governor Wes Moore's January 2026 announcement of overdose deaths reaching a ten-year low emphasized treatment expansion, naloxone distribution, and point-of-service drug checking—the infrastructure Maryland built when federal leadership remained absent or hostile.

The question SB 562 poses isn't whether Maryland should expand buprenorphine access. Clinical evidence, fiscal analysis, and four years of declining mortality already answered that. The question is whether Maryland will build systems that make expanded access functional rather than theoretical.

Pharmacists can prescribe buprenorphine under federal law as of December 2025. States that fail to construct corresponding regulatory frameworks won't prevent prescribing, but they'll create confusion that discourages pharmacists from exercising authority they legally possess. Maryland can lead by clarifying scope of practice, establishing reimbursement mechanisms, supporting collaborative agreements, and integrating pharmacist prescribing into existing treatment infrastructure.

Or Maryland can wait—watch other states experiment with implementation models, observe outcomes, adjust accordingly. That cautious approach carries its own risks measured in people who die waiting for treatment that exists but remains unreachable because the pharmacy three blocks from their apartment doesn't know it can help.

The 1,315 Maryland residents who died from drug overdoses in 2025 represent a 10-year low and an ongoing catastrophe. Every regulatory barrier removed, every access point added, every prescriber trained moves the needle toward the outcome public health demands: keeping people alive until they're ready for recovery, and ensuring treatment remains available when that readiness arrives.

SB 562 passed through the House committee Tuesday without recorded opposition. Whether it becomes law, how Maryland implements federal authorization, and whether pharmacists across the state complete training and begin prescribing will determine if this moment marks genuine expansion or another missed opportunity to translate policy into lives saved.

For now, the path exists. Whether Maryland walks it depends on decisions made in coming weeks by legislators who control funding, regulators who write rules, insurance companies that determine reimbursement, and pharmacists who decide whether eight hours of training is worth the responsibility of prescribing medication that might keep someone's neighbor, coworker, or family member alive long enough to rebuild a life that addiction nearly destroyed.